openPR Logo
Press release

New Confirmed Delegates & Speakers for RNA Therapeutics

10-26-2017 03:53 PM CET | Science & Education

Press release from: SMi Group

SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!

Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led Arrowhead’s acquisition of the Novartis RNAi assets and led Arrowhead’s $670 Million cardiovascular deal with Amgen. Dr. Hamilton previously served as CEO of Calando Pharmaceuticals. He earned an MD and MBA at The Ohio State University and is board certified in Emergency Medicine.

We had the chance to interview Dr. Hamilton about his background and career experience.

Below is a snapshot of his interview:

Q. What do you believe are the biggest challenges associated with developing an RNA Therapeutic?

A. Identification of novel targets that can be modulated with available delivery technologies.

Q. What lessons can be learnt following several years of RNA-based therapeutic development?

A. Scientific endeavors such as the development of a new therapeutic class will inevitably be met with breakthroughs and setbacks. Learning from one’s mistakes and persistence are key.

Check out the full interview, available in the download centre. www.therapeutics-rna.com/opr

Hear more from Dr. James Hamilton at RNA Therapeutics this February 2018, as he presents 'The Evolution of RNAi Delivery at Arrowhead'.

RNA Interference is used to silence genes before it produces the protein, which is harmful for the body. However, in order for this to be effective, ways to safely and effectively deliver this therapeutic to its target must also be developed. Arrowhead Pharmaceuticals is one of the companies leading this search. This presentation will cover the previous technologies Arrowhead have used, analyse the changes that have been made to improve the technologies and look at the potential of Arrowhead’s current synthetic siRNA delivery systems including dynamic PolyConjugates.

Topics will explore:

- Older RNAi delivery technologies
- Dynamic Polyconjugates: Pre-clinical and Clinical Experience
- Arrowhead Single Molecule RNAi Conjugates

Latest Confirmed Delegates:

Evonik Nutrition & Care GmbH | Heptares Therapeutics | N4 Pharma UK Limited | The Italian Institute of Technology | University Of Twente / 20Med

For those looking to attend there is currently a £400 early-bird saving, ending October 31st

Further information is available at: www.therapeutics-rna.com/opr

SMi presents the 9th Annual Conference:
RNA Therapeutics
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Website: www.therapeutics-rna.com/opr

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

1 Westminster Bridge Rd, London SE1 7XW

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Confirmed Delegates & Speakers for RNA Therapeutics here

News-ID: 788669 • Views: 1266

More Releases from SMi Group

Exclusive updates on the UK MoD’s LE TacCIS Programme at Future Armoured Vehic …
SMi Reports: Senior representative from the UK MoD will be presenting updates on the LE TacCIS programme at the conference in London, next April SMi Group’s 5th Annual Future Armoured Vehicles Situational Awareness Conference will be held on the 1st and 2nd April 2020, in London. The event provides a great opportunity to collaborate with technical leads, platform managers and programme directors to share their insights on the latest systems
Pharma Microbiology UK Conference to discuss Environmental Monitoring
SMi Reports: The Pharmaceutical Microbiology UK conference, taking place on 20 and 21 January 2020 in London, will include a variety of innovative presentations from the environmental monitoring field. With the slowdown in world economic growth, the Pharmaceutical & Biotechnology Environmental Monitoring industry has suffered a certain impact. However, it has still maintained a relatively optimistic growth over the past four years, as the market size maintained an annual growth rate
Exclusive platform updates on the ASCOD, AJAX, Challenger 2, Warrior IFV, PATRIA …
SMi Reports: Senior experts to present exclusive communication and systems updates at the Future Armoured Vehicles Situational Conference in London, next April SMi Group’s 5th Annual Future Armoured Vehicles Situational Awareness will commence on the 1st and 2nd April 2020, in London. The conference will delve deeper into the role of industry, inviting technical leads, platform managers and programme directors to share their insights on the latest systems and sub-systems, providing
Registration Opens for Future Armoured Vehicles Situational Awareness 2020 in Lo …
SMi reports: The agenda has been released for the upcoming Future Armoured Vehicles Situational Awareness Conference, taking place in London in April 2020. In an increasingly complex and congested digital battlespace, the need to provide near real-time information on the whereabouts of an adversary’s location and intent, using enhanced situational awareness capabilities, is vital in aiding armoured units to respond quickly to incoming threats. It is therefore imperative for defence forces

All 5 Releases


More Releases for RNA

RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
Topics Presented this February 2018 at RNA Therapeutics
SMi’s RNA Therapeutics will be bringing a global presence from MHRA, The RNA Institute, MiNA Therapeutics, AstraZeneca R&D, GSK, Sanofi, CureVac and more. With an agenda full of exciting and new approaches, examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches and patenting RNA Therapeutics. www.therapeutics-rna.com/opr Spotlight: Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis? Have questions answered during
RNA Analysis Market worth 3.62 billion USD by 2021
RNA Analysis Market size was around USD 1.89 billion in 2016. It is expected to grow at a CAGR of 13.9% to reach USD 3.62 billion by 2021. The market is mainly driven by the increasing technological advancements, increasing investment in research and development by biotechnology and pharmaceutical companies, rising government and private funding, and growing preference for personalized medicines. However, lack of skilled professionals in the transcriptomics field and lack
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and